This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Company News for Jul 28, 2022
by Zacks Equity Research
Companies In The News Are: BSX, TMUS, WM, ROK.
Boston Scientific (BSX) Q2 Earnings Beat, Margins Decline
by Zacks Equity Research
Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.
Boston Scientific (BSX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 4.76% and 0.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Earnings Due on Jul 27: BSX, HOLX & ALGN
by Urmimala Biswas
MedTech companies' results are likely to reflect a rebound in the base business. Let's see how BSX, HOLX and ALGN fare this time.
PETQ vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
PETQ vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Boston Scientific (BSX) in Q2 Earnings?
by Zacks Equity Research
Within the PI business of Boston Scientific (BSX), Q2 sales are expected to have been strong, banking on the strong performance of the drug-eluting franchise.
The Zacks Analyst Blog Highlights Adobe, The Southern Company, Northrop Grumman, Boston Scientific, Marathon Petroleum and Archer-Daniels-Midland
by Zacks Equity Research
Adobe, The Southern Company, Northrop Grumman, Boston Scientific, Marathon Petroleum and Archer-Daniels-Midland have been included in this Analyst Blog.
Top Research Reports for Adobe, Southern Company & Northrop Grumman
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), The Southern Company (SO), and Northrop Grumman Corporation (NOC).
Boston Scientific (BSX) to Broaden Stent Portfolio With Buyout
by Zacks Equity Research
According to Boston Scientific (BSX), M.I.Tech's product offerings complement the company's existing stent portfolio, including the differentiated AXIOS Stent and Electrocautery Enhanced Delivery System.
Here's Why You Should Retain Boston Scientific (BSX) for Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) strong organic sales and notable acquisitions.
Boston Scientific (BSX) Gains from New Buyouts, FX Issue Ails
by Zacks Equity Research
Boston Scientific (BSX) is currently looking forward to launching its arterial and venous offerings in the second half of 2022.
Boston Scientific (BSX) Down 6.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Analyst Reports for Adobe, Danaher, Equinor & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), Danaher Corporation (DHR), and Equinor ASA (EQNR).
Boston Scientific (BSX) Q1 Earnings Top, 2022 Revenue View Up
by Zacks Equity Research
Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.
Boston Scientific (BSX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.63% and 2.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stock Earnings Roster for Apr 27: BSX, HOLX & More
by Riya Anand
Medical device stocks' Q1 earnings will likely reflect rebound in base business. Let's see how Boston Scientific (BSX), Hologic (HOLX), Align Technology (ALGN) and Integra (IART) will fare in Q1.
Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Boston Scientific (BSX) in Q1 Earnings?
by Zacks Equity Research
Given an innovative pipeline, expansion into faster growth markets, globalization efforts and enhanced digital capabilities, Boston Scientific (BSX) is well-positioned to register strong first quarter of 2022 results.
Why Boston Scientific (BSX) Could Beat Earnings Estimates Again
by Zacks Equity Research
Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Retain Boston Scientific (BSX) For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) robust organic sales and strategic buyouts.
Boston Scientific (BSX) Hurt by Price and Volume Issues
by Zacks Equity Research
The current headwinds around Boston Scientific (BSX) include the cost of running plants with COVID-specific measures, increased freight costs, price pressure and higher direct labor wages.
Boston Scientific (BSX) Up 3.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Stock Reports for Eli Lilly, Union Pacific & Freeport-McMoRan
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Union Pacific Corporation (UNP), and Freeport-McMoRan Inc. (FCX).
Boston Scientific (BSX) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in legacy business from pandemic mayhem.